Stephen Hawser
Overview
Explore the profile of Stephen Hawser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
718
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Belley A, Morrissey I, Hawser S, Kothari N, Knechtle P
J Glob Antimicrob Resist
. 2021 Mar;
25:93-101.
PMID: 33746112
Objectives: This study aimed to investigate third-generation cephalosporin (3GC) resistance determinants [extended-spectrum β-lactamases (ESBLs), AmpC β-lactamases and OXA-type β-lactamases] in contemporary clinical Enterobacterales isolates and to determine the in vitro...
12.
Huang D, Charrier C, Hawser S
Diagn Microbiol Infect Dis
. 2020 Feb;
97(1):115013.
PMID: 32081524
Iclaprim is a novel diaminopyrimidine, which inhibits bacterial dihydrofolate reductase, and it is active against Gram-positive pathogens including emerging drug-resistant pathogens. In vitro activity of iclaprim and comparators against 1365...
13.
Lob S, Karlowsky J, Young K, Motyl M, Hawser S, Kothari N, et al.
J Med Microbiol
. 2020 Jan;
69(2):207-217.
PMID: 31976856
Infections attributable to carbapenem-resistant Gram-negative bacilli are increasing globally. New antimicrobial agents are urgently needed to treat patients with these infections. To describe susceptibility to the novel carbapenem-β-lactamase inhibitor combination...
14.
Hawser S, Kothari N, Karlowsky J, Wiktorowicz T, Hamed K
Diagn Microbiol Infect Dis
. 2020 Jan;
96(4):114978.
PMID: 31952866
Ceftobiprole was active (MIC, ≤2 mg/L) against most isolates (99.7%; 877/880) of methicillin-resistant Staphylococcus aureus from respiratory tract infections collected in 14 European countries during 2016-2017. Whole-genome sequence analysis showed...
15.
Morrissey I, Olesky M, Hawser S, Lob S, Karlowsky J, Corey G, et al.
Antimicrob Agents Chemother
. 2019 Dec;
64(3).
PMID: 31843999
Eravacycline is a novel, fully synthetic fluorocycline antibiotic developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. Here, we evaluated the activities of eravacycline and...
16.
Morrissey I, Hawser S, Lob S, Karlowsky J, Bassetti M, Corey G, et al.
Antimicrob Agents Chemother
. 2019 Dec;
64(3).
PMID: 31843997
Eravacycline is a novel, fully synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by resistant Gram-positive pathogens. Here, we evaluated the activities of eravacycline...
17.
Lob S, Karlowsky J, Young K, Motyl M, Hawser S, Kothari N, et al.
J Antimicrob Chemother
. 2019 May;
74(8):2284-2288.
PMID: 31086960
Objectives: Relebactam is a diazabicyclooctane non-β-lactam inhibitor of Ambler class A and C β-lactamases that is in clinical development in combination with imipenem/cilastatin. The current study evaluated the in vitro...
18.
Huang D, Charrier C, Le Bras C, Hawser S, Noviello S
J Med Microbiol
. 2019 May;
68(6):898-902.
PMID: 31050628
The incidence and patient outcomes of Staphylococcus aureus isolates by iclaprim MIC was determined among patients from two phase 3 studies for the treatment of acute bacterial skin and skin...
19.
Morrissey I, Magnet S, Hawser S, Shapiro S, Knechtle P
Antimicrob Agents Chemother
. 2019 Apr;
63(7).
PMID: 30988152
Enmetazobactam, formerly AAI101, is a novel penicillanic acid sulfone extended-spectrum β-lactamase (ESBL) inhibitor. The combination of enmetazobactam with cefepime has entered clinical trials to assess safety and efficacy in patients...
20.
Noviello S, Magnet S, Hawser S, Huang D
Antimicrob Agents Chemother
. 2019 Jan;
63(4).
PMID: 30642922
Iclaprim, a selective bacterial dihydrofolate reductase inhibitor, and other antibiotics were tested against Gram-positive isolates from two phase 3 studies of acute bacterial skin and skin structure infections (ABSSSIs) (REVIVE-1...